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This study isolated and characterized the West Nile virus (WNV) putative receptor molecule(s) from Aedes albopictus mosquito (C6/36)
cells. The binding of WNV to C6/36 cells was saturated with 5000 particles per cell. The entry of WNV into C6/36 cells was strongly
inhibited when pretreated with proteinase K and to a lesser extent with sodium periodate. However, pretreatment of C6/36 cells with
phospholipases, glycosidases, heparinases and neurimidase had no effect on virus entry. By using virus overlay protein blot assay, WNV was
observed to bind to the 140-kDa, 95-kDa, 70-kDa and 55-kDa plasma membrane-associated molecules isolated from C6/36 cells. Murine
antibodies generated against the 95-kDa and 70-kDa membrane proteins effectively blocked WNV, Japanese encephalitis virus (JEV) and
Dengue virus (DV) serotype 2 infection in C6/36 cells. In addition, the binding of the recombinant-WNVenvelope domain III protein to C6/
36 cells can be inhibited by the anti-95-kDa and anti-70-kDa membrane protein antibodies. These data strongly supported the possibility that
the 95-kDa and 70-kDa plasma membrane-associated proteins are part of a receptor complex for mosquito-borne flaviviruses (WNV, JEVand
DV) on mosquito cells.
D 2005 Elsevier Inc. All rights reserved.Keywords: Flavivirus; Virus entry; Receptor; Mosquito cells; Virus bindingIntroduction
West Nile virus is a small enveloped virus and a member
of the Japanese encephalitis virus serocomplex of the genus
Flavivirus in the family Flaviviridae. West Nile virus is the
causative agent of West Nile fever. A spectrum of associated
complications (meningo-encephalitis and acute flaccid
paralysis) has caused many fatalities in immuno-compro-
mised individual (Nedry and Mahon, 2003). The first
known human case of WNV infection in the Western
Hemisphere (New World) was reported in August 1999
(CDC, 1999). Since 1999, WNV has spread across the
eastern and southern states and into central United States
(O’Leary et al., 2004). It was speculated that the movement
of WNV to the Western hemisphere was caused by0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: micngml@nus.edu.sg (M.L. Ng).migratory birds that acted as introductory hosts and perhaps
by infecting ornithophilic mosquitoes (Rappole et al., 2000).
The WNV is transmitted to vertebrate hosts mainly from the
inoculation of virus harboring mosquitoes of the Culex,
Aedes, Anopheles, Minomyia and Mansonia species in
Africa, Asia and the United States (Burke and Monath,
2001; Ilkal et al., 1997).
Mature WNV consists of three structural proteins: the
large envelope glycoprotein (E), the nucleocaspid protein
(C) and the membrane protein (M). Within the virion is a
single-stranded positive sense, infectious RNA genome
(Brinton, 2002). Crystallography data on the ectodomain
of the E protein of tick borne encephalitis virus (Rey et al.,
1995) revealed that the E protein forms homodimers
arranged in a head-to-tail orientation and lies relatively flat
on the virion surface. Each monomer of the E protein is
folded into three distinct domains: a central domain
designated as domain I, an elongated dimerization region05) 249 – 260
Fig. 1. Specific binding of 35S-methionine-labeled WNV to the surface of
C6/36 cells. The saturation of WNV binding to C6/36 cells can be achieved
at approximately 5000 virus particles per cell. The radioactive counts from
triplicates are averaged.
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modules (Rey et al., 1995). Domain II of the E protein is
responsible for low pH-dependent fusion of the virus E
protein to the late endosomal membrane during uncoating
(Rey et al., 1995; Kuhn et al., 2002; Chu and Ng, 2004a).
Domain III of the E protein is postulated to function as the
receptor binding domain of the virus.
Chu et al. (2005) has recently shown the antagonist effect
of soluble recombinant WNV E domain III protein on
binding and entry of WNV into mammalian and mosquito
cells. In addition, monoclonal and polyclonal antibodies
generated against domain III of flavivirus E protein are
highly effective in neutralizing the viruses (Volk et al., 2004;
Beasley and Barrett, 2002; Crill and Roehrig, 2001; Chu et
al., 2005). Mutagenesis of flavivirus domain III of the E
protein also alters the entry process and virulence of viruses
(Vlaycheva and Chambers, 2002; Lee and Lobigs, 2000).
A number of putative cellular receptors (glycosamino-
glycans, DC-SIGN, laminin receptor, BiP, aVh3 integrin,
Hsp70 and Hsp90) have been identified for mosquito-borne
flaviviruses in different mammalian cell types (Chen et al.,
1997; Navarro-Sanchez et al., 2003; Tassaneetrithep et al.,
2003 Jindadamrongwech et al., 2004; Thepparit and Smith,
2004; Chu and Ng, 2004b; Reyes-Del Valle et al., 2005) but
none has been identified in mosquito cells. Little is currently
known about the initial interaction of mosquito-borne
flaviviruses including WNV with mosquito cells. Thus, this
study attempts to isolate and characterize putative plasma
membrane-associated molecule(s) from mosquito cells (C6/
36) that bind and mediate infectious entry of WNV.Results
Binding of WNV to C6/36 cells
To determine the involvement of receptor–ligand bind-
ing of WNV onto C6/36 cells, a virus–cell binding assay
was first carried out. A constant number of C6/36 cell (1 
103 cells) was incubated with increasing amounts of 35S-
methionine-labeled WNV for a period of 1 h. Unbound or
excess virus was removed by washing extensively with
PBS. The amount of virus bound to cells was quantified in
triplicate by scintillation counting. The data showed that
WNV binding to C6/36 cells can be saturated at levels of
approximately 5000 virus particles per cell within 1 h of
virus inoculation (Fig. 1). The binding of WNV to C6/36
cells was both dosage-dependent and occurred in a saturable
fashion, suggesting the importance of the receptor-depend-
ent binding of WNV to C6/36 cells.
Isolation of putative WNV binding receptor molecule(s)
from the plasma membrane of C6/36 cells
Virus overlay protein blot assay (VOPBA) was first used
to identify the putative receptor molecule(s) that bind WNVfrom the prepared plasma membrane proteins of C6/36 cells.
Virus overlay protein blot assay was used successfully to
identify and characterize receptor molecules for a number of
viruses in different cell types (Choi et al., 1990; Borrow and
Oldstone, 1992; Cao et al., 1998; Bruett et al., 2000; Chu
and Ng, 2003). Equal quantities of the plasma membrane
proteins were separated by SDS-PAGE and transferred onto
nitrocellulose membrane. The membrane were cut into strips
and incubated with radiolabeled WNV. Binding of the
radiolabeled virus on the membrane is detected by exposing
the membrane strips to X-ray films.
Using VOPBA, WNV was observed to bind to a series of
protein bands of different molecular masses (55 kDa, 70
kDa, 95 kDa and 140 kDa) in the plasma membrane
preparations of C6/36 cells (Fig. 2a). The 95-kDa and 70-
kDa protein bands exhibited much stronger virus binding as
compared to the rest of the protein bands. To ensure that
these bands were not contributed by the non-specific
binding of residual radioisotopes in the supernatant, the
supernatants of uninfected cells prepared accordingly to the
WNV-infected cells were also incubated under the same
conditions. No bands were observed on the membrane
incubated with the supernatant of uninfected cells (Fig. 2b).
The specificity of the radiolabeled virus binding to the series
of bands was further confirmed by using a high-salt buffer
wash (with 200 mM of NaCl). The WNV binding to the
140-kDa and 55-kDa bands was no longer detectable after
the membrane strip was being washed with the high-salt
buffer (Fig. 2c), hence indicating that WNV has lower
affinity binding or non-specific binding to the 140-kDa and
55-kDa protein bands.
Biochemical characterization of putative West Nile virus
receptor molecule(s) on C6/36 cells
Two-pronged approaches (cellular and VOPBA) were
used to characterize the biochemical nature of these
Fig. 2. West Nile virus binds to isolated plasma membrane-associated
proteins from C6/36 cells using VOPBA. Plasma membrane-associated
proteins from C6/36 cells were extracted under non-denaturing conditions,
separated by SDS-PAGE and transferred to nitrocellulose membrane. 35S-
methionine-labeled WNV binding to the membrane protein bands was
detected by exposing to X-ray film. (a) WNV binds to C6/36 plasma
membrane-associated protein bands of molecular masses 140 kDa, 95 kDa,
70 kDa and 55 kDa. (b) No band is observed from proteins purified from
supernatants of 35S-methionine-labeled radio-labeled uninfected cells,
hence indicating the specific binding of WNV to the plasma membrane
proteins of C6/36 cells. (c) Highly specific binding of WNV to the 95-kDa
and 70-kDa membrane protein bands is noted in the presence of high
stringent washing conditions (200 mM of NaCl and 0.05% Tween 20).
Binding of WNV to the 140-kDa and 55-kDa membrane protein bands is
totally abolished under these stringent conditions. Molecular size markers
are indicated on the right of each membrane blot.
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biochemical nature of the putative WNV receptor mole-
cule(s) on the surface of intact mosquito (C6/36) cells was
first characterized by pre-treating C6/36 cells with a panel
of enzymes (phospholipases, proteases and glycosidases)
or sodium periodate that would destroy the individual
membrane components (e.g., lipids, proteins and carbohy-
drates). The concentrations of the enzymes and sodium
periodate used in this study have been shown to
effectively inhibit the entry of several viruses (Borrow
and Oldstone, 1992; Ramos-Castaneda et al., 1997; Chu
and Ng, 2003). The treated C6/36 cells were tested for
cellular viability by Cytotox 96 non-radioactive cytotox-
icity assay kit (Promega) and morphological observation
under the microscope before proceeding for WNV
infection. Minimal cytotoxicity was observed in the
treated C6/36 cells. The ability of the treated cells to
mediate WNV binding and subsequent infectious entry
was determined by plaque assays. Results shown in Fig. 3
were expressed as the number of log10 unit inhibition with
respect to the untreated samples.
Treatment of C6/36 cells with the three phospholipases
(A, C and D) did not substantially inhibit the infectious
entry of WNV (Fig. 3a). Furthermore, pretreatment of C6/36
cells with glycosidases (a-mannosidase, endoglycosidase,
a-fucosidase, O-glycosidase, neurimidase), heparinases and
lectins (wheat germ agglutinin, concanavalin A, phytohe-magglutinin) did not significantly prevent the infectious
entry of WNV into C6/36 cells (Figs. 3b and c, respec-
tively). Despite the lack of inhibition of WNVentry after the
treatment of C6/36 cells with a different range of
glycosidases, sodium peroidate (acts by oxidizing cell-
surface carbohydrate residues while not affecting cell
surface protein or lipid epitopes) was capable of reducing
WNV entry into C6/36 cells in a dosage-dependent manner
(Fig. 3b). In addition, pretreatment of C6/36 cells with both
serine and thiol proteases strongly inhibit WNV entry in a
dosage-dependent manner (Fig. 3d). Proteinase K (an
endolytic protease that cleaves peptide bonds) strongly
inhibits WNV infection with approximately a 4-log10
reduction. Based on the results obtained above, it suggests
that the WNV receptor molecule(s) on the surface of C6/36
cells are predominantly proteineous in nature and with
possibility of some degree of glycosylation (sensitive to
sodium peroidate).
To affirm the above observations, the biochemical
nature of the putative WNV binding receptor molecule(s)
was also reassessed via VOPBA. Fig. 4a shows the
binding of WNV to the 140-kDa, 95-kDa, 70-kDa and
55-kDa membrane protein bands in the absence of
biochemical treatments. Proteinase K treatment of the
separated C6/36 plasma membrane-associated proteins
reduced WNV binding at the concentration of 0.01 Ag/
ml (Fig. 4b) and totally abolished WNV binding to all the
protein bands at the concentration of 0.1 Ag/ml (Fig. 4c),
whereas treatment of the membrane proteins with phos-
pholipases did not affect virus binding to all the protein
bands (Fig. 4d). However, the binding of WNV to the 95-
kDa, 70-kDa and 55-kDa plasma membrane-associated
proteins was drastically reduced upon treatment with 10
mM sodium periodate (Fig. 4e) but not for the 140-kDa
protein band.
Inhibition of WNV entry into C6/36 cells with murine
polyclonal antibodies against the putative WNV receptor
molecules
The 140-kDa, 95-kDa, 70-kDa and 55-kDa plasma
membrane proteins isolated from C6/36 cells were used to
generate polyclonal antibodies in mice. The crude murine
sera were purified using columns to obtained IgG anti-
bodies for the subsequent experiments. The specificity of
the murine polyclonal antibodies generated against these
isolated plasma membrane proteins was checked by
Western blot assay. Antibodies against the different
molecular mass proteins were able to detect their respec-
tive membrane proteins specifically (Fig. 5, Lanes 1, 3, 5
and 7). No bands were detected with the separated
membrane proteins when incubated with pre-immune sera
(Fig. 5, Lanes 2, 4, 6 and 8).
To affirm the role of these putative membrane proteins in
mediating the entry of WNV into C6/36 cells, a series of
WNV entry blockage studies were performed with the
Fig. 3. Biochemical characterization of WNV-binding molecules present on the surface of intact C6/36 cells. (a) Pretreatment of C6/36 cells with
phospholipases does not significantly reduce the infectious entry of WNV. In addition, WNV infection is resistant to the effect of (b) glycosidases,
heparinases and (c) lectins. However, C6/36 cells pretreated with sodium periodate (b) are capable of inhibiting the infectious entry of WNV in a dosage-
dependent manner. (d) Pretreatment of C6/36 cells with a panel of proteases exhibited significant inhibition of WNV infectious entry in a dosage-
dependent manner. Proteinase K has the most potent inhibitory effect on WNV infection, resulting in 4-log unit reduction of virus yield at the
concentration of 0.1 Ag/ml.
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kDa, 95-kDa, 70-kDa and 55-kDa plasma membrane-
associated proteins. The specific membrane protein anti-
bodies were first incubated with C6/36 cells before virus
infection (WNV, JEV, DV and Poliovirus). Fig. 6a shows
that murine polyclonal antibodies against 70-kDa membrane
proteins exhibited the strongest inhibitory effect on the
binding and entry of WNV into C6/36 cells. The antibodies
against the 95-kDa membrane protein was also capable of
reducing WNV entry into C6/36 cells while antibodies
against the 140-kDa and 55-kDa membrane proteins had
minimal inhibitory effect on WNV binding and subsequent
entry into C6/36 cells.
The localization of WNV with the 95-kDa or 70-kDa
membrane proteins was assessed by immunofluorescence
assays. WNV was first incubated with C6/36 cells for 30
min at 4 -C and processed for double indirect immunostain-ing with antibodies against the membrane proteins (95 kDa
and 70 kDa) and WNV. Figs. 6b and c show strong co-
localization signal of WNV with the 95-kDa and 70-kDa
membrane proteins, respectively. West Nile virus was
observed in close association with the 95-kDa and 70-kDa
membrane proteins (arrows) which exhibited typical local-
ization pattern of plasma membrane-associated proteins.
Interestingly, the entry of both JEV and DV (serotype 2)
was also significantly reduced by the anti-70-kDa and anti-
95-kDa membrane protein antibodies in a similar trend as
with WNV (Figs. 6d and e, respectively). In contrast, the
entry of poliovirus (non-related virus) was not affected by
the antibodies’ blockage against all the membrane proteins
(Fig. 6f). Therefore, these results suggested that the 70-kDa
and 95-kDa plasma membrane-associated proteins played a
role as common receptor molecules for mediating the entry
of WNV, JEV and DV into C6/36 cells.
Fig. 4. Biochemical characterization of WNV-binding plasma membrane-associated protein on VOPBA. (a) WNV binds to the C6/36 membrane protein of 140
kDa, 95 kDa, 70 kDa and 55 kDa in the absence of enzymes or biochemical treatments. (b) Proteinase K (0.01 Ag/ml) treatment of the membrane proteins on
nitrocellulose membrane reduces WNV binding to all the membrane protein bands isolated from C6/36 cells. (c) The binding of WNV to the membrane protein
was totally abolished after treatment with proteinase K at the concentration of 0.1 Ag/ml. No bands are observed. (d) WNV binding to the 140-kDa, 95-kDa, 70-
kDa and 55-kDa membrane proteins is not affected after phospholipase A treatment (10 U/ml). (e) Pretreatment of the C6/36 plasma membrane proteins with
10 mM of sodium peroidate shows inhibition of WNV binding to the 95-kDa, 70-kDa and 55-kDa membrane protein bands but has no effect on the 140-kDa
protein band. Molecular size markers are indicated on the right of each membrane blot.
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antibodies blocked recombinant WNV E domain III protein
binding to C6/36 cells
Recent studies have identified that the recombinant WNV
E domain III of the flavivirus envelope protein is responsible
for binding to cellular receptors (Mukhopadhyay et al., 2003;
Volk et al., 2004; Chu et al., 2005). The ability of antibodies
against the putative receptor molecule(s) blocking the
binding of WNV E domain III protein was assessed. West
Nile virus E domain III protein was expressed, purified and
labeled with FITC as described in Materials and methods.
C6/36 cells were pre-incubated with antibodies against the
140-kDa, 95-kDa, 70-kDa or 55-kDa membrane proteins
followed by the FITC-labeled WNV E domain III protein.
Both antibodies against the 95-kDa and 70-kDa membrane
proteins substantially blocked the binding of DIII protein toFig. 5. Immuno-detection of C6/36 membrane proteins with murine polyclonal anti
cells. Detection of C6/36 membrane proteins with pre-immune sera (Lanes 2, 4, 6
(Lane 5) and anti-55-kDa (Lane 7) protein polyclonal antibodies was performed. T
generated are highly specific for its respective membrane proteins from C6/36 celC6/36 cells in a dosage-dependent manner (Fig. 7). How-
ever, minimal blockage of FITC-labeled WNV E domain III
protein to the C6/36 cells was observed by the anti-140-kDa
and anti-55-kDa membrane protein antibodies.
Together, these results have provided strong evidence
that the 95-kDa and 70-kDa membrane proteins are possible
cellular receptor or part of the receptor complex for WNV
and, possibly, JEV and DV (serotype 2) into C6/36 cells.Discussion
The infectious entry of virus into host cells is mediated
by the initial interaction of the virus attachment protein
(VAP) and the cellular receptor molecules. The interaction
of VAP and its cellular counterpart is known to contribute to
host range, tissue tropism and viral pathogenesis. Extensivebodies produced from plasma membrane-associated protein extract of C6/36
and 8) and the anti-140-kDa (Lane 1), anti-95-kDa (Lane 3), anti-70-kDa
he anti-140-kDa, 95-kDa, 70-kDa and 55-kDa murine polyclonal antibodies
ls. Molecular size markers are indicated on the left of each membrane blot.
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entry process of mosquito-borne flaviviruses into different
mammalian cell types (Anderson, 2003). So far, not much is
known about the initial interaction of mosquito-borne
flaviviruses with mosquito cells.
To our knowledge, this is the first study that charac-
terized the putative cellular counterparts from mosquito cellsthat mediate WNV binding and entry. Studies have shown
that WNV can be isolated from Culex, Aedes, Anopheles,
Minomyia and Mansonia mosquitoes (Burke and Monath,
2001; Ilkal et al., 1997). Hence, this study utilized the Aedes
albopictus cell line (C6/36) that has been shown to be
highly susceptible to WNV infection (Turell et al., 2001),
and WNV has also been isolated from field strains of A.
ig. 6. West Nile virus interacts with the 95-kDa and 70-kDa plasma membrane-associated proteins of C6/36 cells. Antibody blockage assay of WNV
fectious entry was carried out using antibodies against the 140-kDa, 95-kDa, 70-kDa and 55-kDa membrane proteins. (a) A dosage-dependent inhibition o
NV infection with the anti-95-kDa and anti-70-kDa membrane protein antibodies is noted but not with antibodies generated against the 140-kDa and 55-kDa
embrane proteins. The immuno-fluorescence detection of WNV binding to the (b) 95-kDa (arrows) and (c) 70-kDa (arrows) plasma membrane-associated
roteins is shown. WNV is stained with Texas Red-conjugated monoclonal antibodies and the plasma membrane 95-kDa and 70-kDa receptor proteins are
tained with FITC-conjugated respective polyclonal antibodies. The co-localization of WNV particles with the 95-kDa or 70-kDa membrane proteins (dots) can
e clearly observed. Similarly, the murine polyclonal antibodies against the 95-kDa or the 70-kDa membrane proteins are capable of reducing (d) JEV and (e
V infection in C6/36 cells. (f) In contrast, poliovirus infection of C6/36 cells is not affected in the presence of antibodies against the panel of WNV-binding
embrane proteins. Triplicate results are expressed as log10 unit reduction of WNV infection at a given antibody concentration. Preimmune sera are included to
nsure that the inhibitory effect on WNV infection is not due to non-specific blockage by the murine antibodies.
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ealbopictus mosquitoes. The ability of flavivirus to infect a
cell line derived from a particular arthropod vector can
reflect the natural vector-virus relationships (Mussgay et al.,
1975; Lawrie et al., 2004), thus providing information about
virus transmission and viral persistence in the natural
environment. In this study, WNV was shown to bind
specifically to C6/36 cells in a dose-dependent and saturable
manner with approximately 5000 virus particles per cell
(Fig. 1). These results displayed the characteristics of typical
ligand-receptor interactions existing, hence suggesting the
presence of a specific interaction between WNV and
receptor molecule(s) on C6/36 cells.f
)Glycoaminoglycans have been implicated in mediating
the attachment and entry of mosquito-borne flaviviruses
into mammalian cells (Chen et al., 1997; Lee and Lobigs,
2000). It is postulated that the initial binding of
flaviviruses to the cellular surface is mediated by heparan
sulfate and subsequent entry occurring through a high-
affinity receptor (Putnak et al., 1997). However, the
involvement of heparan sulfate in mediating the attach-
ment of flaviviruses to cell surface is not universal, as it
could be dependent on the member of the flavivirus
family, the virus strains, the passage level of the virus
and the cell types (Bielefeldt-Ohmann et al., 2001;
Fig. 7. Recombinant WNV E DIII protein binds to the 95-kDa and 70-kDa putative receptor molecules on C6/36 cells. A dosage-dependent inhibition of FITC-
labeled WNV E DIII protein can be observed in C6/36 cells with pre-incubation of cells with antibodies against the 95-kDa or 70-kDa putative receptor
molecules. In contrast, antibodies specific for the 140-kDa and 55-kDa and the pre-immune sera have minimal effect on WNV E DIII protein binding to C6/36
cells.
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2003).
A recent study by Hung et al. (2004) demonstrated that
the binding of dengue virus envelope domain III (putative
receptor binding domain) to C6/36 cells is independent of
heparan sulfate. In this study, the attachment of WNV to
heparan sulfate in C6/36 cells was assessed by pretreatment
of the cells with heparinases. The infectious entry of WNV
into C6/36 cells was not affected despite the pretreatment of
C6/36 cells with heparinases (Fig. 3). A previous study by
Chu and Ng (2003) has also shown that the binding of
WNV to Vero cells does not require heparan sulfate.
Therefore, it seems that heparan sulfate is not required for
WNV entry in both mosquito and vertebrate cells.
Sialic acids present on the surface of cells are known to
function as attachment factor and cellular receptor mediating
the entry of a number of viruses that include influenza
viruses (Suzuki, 2001), rotavirus (Arias et al., 2002), bovine
parvovirus (Johnson et al., 2004) and equine rhinitis A virus
(Stevenson et al., 2004). The infection of C6/36 cells with
WNV was resistant to neuraminidase pre-treatment, sug-
gesting that sialic acid is not essential for virus binding and
subsequent virus entry into cells (Fig. 3). Salas-Benito and
del Angel (1997) has also reported that treatment of C6/36
cells with neuraminidase does not affect the binding of
dengue virus (serotype 4) to cells.
In addition to the utilization of glycoaminoglycans and
sialic acid as cellular receptors for virus entry into cells,
carbohydrate residues on cellular receptors have also been
reported to be essential for virus binding to the receptors
(Chu and Whittaker, 2004; Ferreira et al., 2004; Spiro-
poulou et al., 2002; Smith and Helenius, 2004). Our
previous study has shown the importance of N-linked
sugars with a-mannose residues on the cellular receptor of
Vero and murine neuroblastoma cells for WNV binding(Chu and Ng, 2003). However, pretreatment of intact C6/
36 cells with a panel of glycosidases that include
endoglycosidase H, O-glycosidase, a-mannosidase, a-
fucosidase and competitive assays with lectins (concanva-
lin-A and phytohemagglutinin) did not exert any effect on
inhibiting the infectious entry of WNV (Fig. 3). It seems
consistent that carbohydrate residues on the surface of C6/
36 cells are not necessary for the binding of WNV and
dengue virus (serotype 4) (Salas-Benito and del Angel,
1997).
A number of putative WNV-binding plasma membrane-
associated molecules (140 kDa, 95 kDa, 70 kDa and 55
kDa) from C6/36 cells were demonstrated by VOPBA in
this study (Fig. 2a). The technique of VOPBA has been used
successfully in the identification of virus receptors on cell
surfaces (Choi et al., 1990; Borrow and Oldstone, 1992; Cao
et al., 1998; Bruett et al., 2000; Chu and Ng, 2003). West
Nile virus was observed to bind specifically to two protein
bands (95 kDa and 70 kDa) from C6/36 cells under high
stringency conditions of high-salt (200 mM) and -detergent
(0.05% Tween 20) washing (Fig. 2b). Biochemical analysis
of these WNV-binding membrane proteins from C6/36 cells
with proteases and sodium periodate treatment (Fig. 3)
strongly suggested the glycoproteineous nature of the
putative receptor molecules.
The production of murine polyclonal antibodies against
the 140-kDa, 95-kDa, 70-kDa and 55-kDa C6/36 cell
plasma membrane-associated proteins showed that poly-
clonal antibodies against the 95-kDa and 70-kDa proteins
were capable of inhibiting the infectious entry of WNV, JEV
and DV (serotype 2) in a dosage-dependent manner. This
result was consistent with a previous study by Chu et al.
(2005) showing that both WNV and DV (serotype 2) may
utilize the same putative receptor molecule on the surface of
C6/36 cells for virus binding and subsequent entry. The
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associated proteins in mediating WNV binding and entry
was further supported by immunofluorescence assay
whereby the binding of WNV to the 95-kDa or 70-kDa
membrane proteins was observed on the cell surface of C6/
36 cells (Figs. 6b and c). Furthermore, minimal blocking
effect on the infectious entry of the unrelated poliovirus
(Fig. 6f) was achieved when C6/36 cells were pre-incubated
with antibodies against the 95-kDa and 70-kDa membrane
proteins.
However, antibodies against the 140-kDa and 55-kDa
membrane proteins (Fig. 6) were not effective in blocking
the infection of C6/36 cells by WNV, JEV and DV
(serotype 2). It was interesting to observe that WNV could
bind to the 140-kDa and 55-kDa membrane proteins in
VOPBA but the antibodies specific for the 140-kDa and
55-kDa membrane proteins failed to prevent infectious
entry of WNV into C6/36 cells. A possible explanation is
that WNV binds to the 140-kDa and 55-kDa membrane
proteins that may associate with the receptor complex that
were extracted in the procedure for VOPBA. However,
these membrane proteins may not serve as the functional
receptor to mediate the entry of WNV into C6/36 cells,
hence, antibodies generated against the 140-kDa and 55-
kDa membrane proteins had no effect on blocking virus
entry into C6/36 cells.
Domain III of the WNV E protein has been reported to
serve as the receptor binding domain (Beasley and Barrett,
2002; Volk et al., 2004; Chu et al., 2005), and this study has
also clearly illustrated that the WNV E domain III protein
can bind to the 95-kDa and 70-kDa receptor molecules with
high specificity. The preincubation of C6/36 cells with
antibodies against the 95-kDa or the 70-kDa membrane
proteins effectively prevented the binding of the WNV E
domain III protein to C6/36 cells (Fig. 6).
Hence, these results showed the specific interactions of
WNV, JEV and DV (serotype 2) with the 95-kDa and 70-
kDa membrane proteins on C6/36 cells for the entry
process. Currently, efforts are directed to determine the
identity of the 95-kDa and 70-kDa membrane proteins via
peptide sequencing. The identification of these putative
receptor molecules would provide insight to their distribu-
tions in both susceptible and non-susceptible mosquito
tissues, hence facilitating the development of vector control
strategies.Materials and methods
Maintenance of cell lines
C6/36 cells, a continuous mosquito cell line (kindly
provided by Professor Akira Igarashi, Japan) derived from
A. albopictus (Diptera: Culicidae) embryonic tissue, were
grown in L-15 medium (GIBCO) containing 10% heat-
inactivated fetal calf serum (FCS) at 28 -C. Vero cells (greenmonkey kidney cells, America Type Culture Collection)
were maintained at 37 -C in Medium 199 (M199; GIBCO)
containing 10% FCS.
Virus growth, radiolabeling and purification
The flaviviruses used in this study were kindly provided
by Professor Edwin Westaway, Australia. West Nile virus
(Sarafend), Japanese encephalitis virus (JEV, Nakayama)
and Dengue virus (New Guinea) were propagated in C6/36
cells throughout this study, and poliovirus was propagated
in Vero cells. The quantification of the viruses was
performed on Vero cells using plaque assay.
Confluent monolayers of C6/36 cells were infected with
WNV at a multiplicity of infection (M.O.I.) of 10. For the
preparation of radiolabeled WNV, at 10 h p.i., cells were
starved in methionine-free medium for 2 h and the medium
was then replaced by 0.5% FCS-L-15 media containing
l-35S-methionine [10 ACi/ml] and 2 Ag/ml actinomycin D
(Sigma, USA). At 48 h p.i., the infected cell culture
supernatant (labeled or non-labeled virus) was harvested.
The infected cell culture supernatant was centrifuged at
5000 rpm for 10 min to remove cell debris before the virus
was concentrated and purified according to the process
described below.
West Nile virus was first concentrated and partially
purified by using a centrifugal filter device (Millipore,
Bedford) at 2000 rpm for 2 h. The partially purified viruses
were then applied onto a 5 ml 25% sucrose cushion for
further purification. Sucrose gradient was centrifuged at
25,000 rpm for 2.5 h at 4 -C in a SW55 rotor. Finally, the
purified virus pellet was resuspended in TNE buffer (50 mM
Tris–HCl, 100 mM NaCl, 1 mM EDTA, pH 7.2). The
resuspended virus was aliquoted, snapped frozen and stored
at 80 -C. The specific infectivity and radioactivity of the
radiolabeled virus preparation were approximately 3  108
PFU/ml and 9  103 cpm/ml, respectively.
Virus-cell binding assay
To determine the binding affinity of WNV to C6/36 cells,
1  103 C6/36 cells were incubated with increasing amounts
of radiolabeled WNV at 4 -C for 1 h. Virus-cell interaction
was carried out at 4 -C to avoid viral penetration. WNV is
added to C6/36 cells in the range of 100, 1000, 2500, 5000,
10,000, 50,000 and 100,000 virus particles per cells. Excess
unbound virus was removed from the cell surface by
washing the cells with PBS for five times. The cells were
then lysed with lysis buffer (10 mM PBS, pH 7.2,
containing 1% Triton X-100 and 0.1% SDS) and the
radioactivity of the cell lysate was determined in a
scintillation counter. Specific binding of WNV to the C6/
36 cells was determined by subtracting the bound CPM
obtained after incubating with the radiolabeled WNV with
the bound CPM due to non-specific binding (obtained from
cells incubated with supernatant of uninfected cells purified
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in triplicates.
Biochemical (protease, phospholipase, glycosidase and
lectins) treatment of C6/36 cells
To assess the biochemical nature of the cellular receptor
molecule(s) on the plasma membrane of C6/36 cells to
which WNV binds, cell monolayers of approximately 8 
105 cells were washed twice with PBS before enzyme
treatment. Cell monolayers were incubated with the
proteases, phospholipases, glycosidases, and lectins in
PBS at pH 7.2 for 45 min at 25 -C. After treatment, cell
monolayers were washed twice with PBS supplemented
with 5% FCS to remove the enzymes. Cell monolayers were
then incubated with WNV (M.O.I. = 10) at 37 -C for 1 h.
Excess virus particles were inactivated with acid glycine
buffer, pH 3.0, for 5 min and the cell monolayer was washed
twice with PBS to remove inactivated viruses. C6/36 cells
were then incubated at 28 -C for 48 h. At 48 h p.i., virus
titers from the treated samples were determined by plaque
assays.
The enzymes used in this study were as described by
Chu and Ng (2003). In brief, the concentrations of the
biochemical used were as follows—proteases: proteinase K
(EC 3.4.21.64) from Tritirachium album (Sigma, USA),
concentrations of 1 and 0.1 Ag/ml; a-chymotrypsin (EC
3.4.21.1) from bovine pancreas (Sigma, USA), concen-
trations of 5 and 0.5 Ag/ml; bromelain (EC 3.4.22.32) from
pineapple stem (Sigma, USA), concentrations of 5, 2.5, and
0.2 mU/ml; papain (EC 3.4.22.2) from Carica papaya
(Roche, USA), concentrations of 25 and 2.5 mU/ml;
phospholipases: phospholipase A2 (EC 3.1.1.4) from
bovine pancreas (Sigma, USA), concentrations of 10 and
1 U/ml; phospholipase C (EC 3.1.1.4.3) from Clostridium
perfringes (Sigma, USA), concentrations of 10 and 1 U/ml;
phospholipase D (EC 3.1.4.4) from peanut (Sigma, USA),
concentrations of 10 and 1 U/ml; glycosidases: endogly-
cosidase H (EC 3.2.1.96) from Streptomyces plicatus
(Roche, USA), concentrations of 10 and 1 mU/ml; O-
glycosidase (EC 3.2.1.97) from Diploccus pneumoniae
(Roche, USA), concentrations of 1 and 0.1 mU/ml; a-
mannosidase (EC 3.2.1.24) from almonds (Sigma, USA),
concentrations of 1000 and 100 Ag/ml; a-fucosidase (EC
3.2.1.11) from almond meal (Sigma, USA), concentrations
of 100 and 10 mU/ml; heparinase I (EC 4.2.2.7) and
heparinase III (EC 4.2.2.2.8) from Flavobacterium hep-
arinum (Sigma, USA), concentrations of 1 and 0.1 U/ml;
lectins: concanavalin-A from Jack bean (Sigma, USA),
wheat germ agglutinin from Triticum vulgaris (Sigma,
USA), phytohemagglutinin from Phaseolus spp. (Wellcome
Diagnostic, UK), concentrations of 1000 and 100 Ag/ml.
Sodium periodate was obtained from Sigma (USA) and the
working concentrations are 10 and 1 mM. Cell viability
after enzyme treatment was assessed by Cytotox 96 non-
radioactive cytotoxicity assay kit (Promega, USA) and byobservation under phase-contrast microscope IX 81(Olym-
pus, Japan).
Extraction and purification of C6/36 plasma
membrane-associated proteins
The plasma membrane proteins were prepared as
previously described by Martinez-Barragan and del Angel
(2001). Monolayers of C6/36 cells were detached with PBS
containing 5 mM EDTA for 10 min at room temperature.
Afterwards, cells were resuspended in ice-cold buffer M
(100 mM NaCl, 20 mM Tris [pH 8], 2 mM MgCl2, 1 mM
EDTA, and 1 mM h-mercaptoethanol) and lysed by 5 to 10
strokes in a tight fitting Dounce homogenizer. Nuclei and
debris were removed by centrifugation at 500  g for 10
min at 4 -C in a Sorvall centrifuge. Membrane proteins were
pelleted from the supernatant by centrifugation at 18,000
rpm for 30 min at 4 -C in a Beckman JA20 rotor and re-
suspended in buffer M without h-mercaptoethanol. The
integrity of extracted membrane proteins was determined as
described by Atkinson and Summers (1971). The concen-
tration of the protein was determined by Bradford assay
with bovine serum albumin [(BSA) (CSL, Australia)] as the
standard. Approximately 750 Ag of proteins was obtained.
The membrane protein preparation was aliquoted and stored
at 20 -C.
Virus overlay protein blot assay (VOPBA)
For the binding of WNV to putative molecules on the
plasma membrane of C6/36 cells, VOPBA was carried out
as essentially described by Martinez-Barragan and del
Angel (2001). In brief, 80 Ag of the plasma membrane
proteins was first separated by 12% SDS-PAGE and
electrophoretically transferred onto nitrocellulose membrane
(Bio-Rad, USA). The nitrocellulose membrane was soaked
overnight in a milk buffer (5% skim milk and 0.5% BSA—
to block non-specific-binding sites and to allow renaturation
of the separated proteins) before rinsing with PBS (three
times) and incubated with the purified radiolabeled WNV
(1  103 cpm/ml). Non-specific binding of the virus
particles was reduced by washing with a high-salt buffer
wash as previously described by Chu and Ng (2003). The
presence of virus binding was detected by exposing the
membranes to Kodak X-ray films. Finally, the films were
developed, washed with distilled water and dried.
Enzymes, lectins and chemical treatments of C6/36 plasma
membrane proteins on VOPBA
The plasma membrane proteins of C6/36 cells were first
isolated and prepared for VOPBA as described in the
previous paragraphs. Plasma membrane proteins were
treated with proteinase K (0.01 Ag/ml and 0.1 Ag/ml),
phospholipase A (10 U/ml), lectins sodium periodate (10
mM). The enzymatic effects of the enzymes were inacti-
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then washed thrice with PBS before subjecting for WNV
binding. Purified radiolabeled WNV (1  103 cpm/ml) was
incubated with the membranes and the presence of virus
binding was detected by exposing the membranes to Kodak
X-ray films.
Generation of murine polyclonal antibodies against plasma
membrane-associated proteins from C6/36 cells
The plasma membrane protein bands that bind WNV
were excised from the 12% SDS-PAGE gels, homogenized,
and eluted using electro-eluter (BIO-RAD). The eluted
proteins were incubated with ImmunEasy mouse adjuvant
(Qiagen, USA) at a concentration recommended by the
manufacturer. The antigen–adjuvant mixture was used to
immunize BALB/c mice (Animal Holding Unit, National
University of Singapore) five times peritoneally at 14-day
intervals. Mouse sera were collected 12 days after the last
booster. Mouse sera were purified using Econo-Pac serum
IgG purification kits (Bio-Rad, USA) and dialyzed over-
night with PBS. The purified immunoglobulins were stored
at 20 -C. Sera were tested by Western blotting (Chu and
Ng, 2003) and the protein bands were detected using
chemiluminescence (Ho et al., 2005).
Immunofluorescence detection of putative WNV binding
molecules on C6/36 cells
For immunofluorescence microscopy, cell monolayers
(C6/36) were grown on coverslips in a 24-well tissue culture
plate. The cells were fixed and processed for immunostain-
ing as described in Chu and Ng (2003). The primary
antibodies used were murine polyclonal anti-55-kDa, 70-
kDa, 95-kDa and 140-kDa plasma membrane proteins
(dilution of 1:100) and monoclonal anti-WNV (H546,
Microbix Biosystems Inc, Canada) at a dilution of 1:1000.
Fluorescein isothiocyanate (FITC) and Texas Red (TR)-
conjugated secondary antibodies (Amersham Pharmacia
Biotech) were used. The specimens were viewed under an
inverted microscope (Olympus IX81) with oil immersion
objective. Fluorescence images were captured by digital
camera (Photometrics, USA) and MetaMorph software,
version 6 (Universal Imaging Corporation, USA).
Antibodies blockage assay
Confluent monolayers of C6/36 cells were first washed
thrice with PBS and incubated with pre-immune serum or
the anti-55, 70-, 95-, 140-kDa polyclonal antibodies (1:10
to 1:1000 dilutions) for 1 h at 4 -C. After incubation, cells
were washed thrice with PBS and infected with WNV, JEV,
DenV and poliovirus (M.O.I. = 10). At appropriate time
p.i., supernatants from the virus-infected cells were
processed for plaque assays. Poliovirus infection was used
as a negative control. Similarly, the above procedure wasrepeated with the replacement of WNV with purified
recombinant WNV envelope domain III protein. WNV
envelope domain III protein was expressed and purified as
described in Chu et al. (2005). Recombinant WNV DIII
protein was labeled with FITC using EZ-label FITC protein
labeling kit from Pierce Biotechnology, USA, and was
carried out according to the manufacturer’s instructions.
FITC-labeled WNV envelope DIII protein (750 Ag/ml) was
incubated with C6/36 cells after the addition of anti-55, 70-,
95-, 140-kDa polyclonal antibodies and pre-immune serum
(at a dilution of 1:10, 1:100, and 1:1000). The binding of
FITC-labeled WNV envelope DIII protein to C6/36 cells
was quantified by measuring the amount of fluorescence
emitted using a fluorescent plate reader. The excitation and
emission wavelengths were set at 380 nm and 520 nm,
respectively. The amount of fluorescence measured was
expressed as the number of fold reduction with cells
incubated with the anti-plasma membrane-associated pro-
teins antibodies with respect to the cells incubated with pre-
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